Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Veliparib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Hydroxycarbamide; Paclitaxel
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer; Salivary gland cancer
Focus Adverse reactions; Therapeutic Use

06 Jun 2023 Status changed from active, no longer recruiting to completed.
05 Jun 2018 Results evaluating safety and efficacy of veliparib (n=18) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
04 Jun 2018 Status changed from completed to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com